InterventionsHuman trial

Safety, Tolerability, and Efficacy of Aleniglipron in Doses up to 240 mg in People Living with Obesity: The Phase 2 ACCESS II Trial

ADA Scientific Sessions 2026 Abstract

The paper

Ildiko Lingvay, Robert Kushner, Ania Jastreboff,

Lev Gertsik, Mike (ke) Liu, Antonio E. Civitarese, Christine Ju, Jamie Butcher, Huibin Yue, Aline Barth,

Dallas

ADA Scientific Sessions 2026 Abstract · 5 Jun 2026

Presented at ADA Scientific Sessions 2026 · Poster 2637-P

doi.org/10.2337/db26-2637-p

Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
The New England Journal of Medicine · 4 Oct 2026